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BACKGROUND
Most women with newly diagnosed advanced ovarian cancer have a relapse within 
3 years after standard treatment with surgery and platinum-based chemotherapy. 
The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor 
olaparib in relapsed disease has been well established, but the benefit of olaparib 
as maintenance therapy in newly diagnosed disease is uncertain.
METHODS
We conducted an international, randomized, double-blind, phase 3 trial to evaluate 
the efficacy of olaparib as maintenance therapy in patients with newly diagnosed 
advanced (International Federation of Gynecology and Obstetrics stage III or IV) 
high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or 
fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, 
or both (BRCA1/2) who had a complete or partial clinical response after platinum-
based chemotherapy. The patients were randomly assigned, in a 2:1 ratio, to receive 
olaparib tablets (300 mg twice daily) or placebo. The primary end point was progres-
sion-free survival.
RESULTS
Of the 391 patients who underwent randomization, 260 were assigned to receive 
olaparib and 131 to receive placebo. A total of 388 patients had a centrally confirmed 
germline BRCA1/2 mutation, and 2 patients had a centrally confirmed somatic 
BRCA1/2 mutation. After a median follow-up of 41 months, the risk of disease pro-
gression or death was 70% lower with olaparib than with placebo (Kaplan–Meier 
estimate of the rate of freedom from disease progression and from death at 3 years, 
60% vs. 27%; hazard ratio for disease progression or death, 0.30; 95% confidence 
interval, 0.23 to 0.41; P<0.001). Adverse events were consistent with the known 
toxic effects of olaparib.
CONCLUSIONS
The use of maintenance therapy with olaparib provided a substantial benefit with 
regard to progression-free survival among women with newly diagnosed advanced 
ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progres-
sion or death with olaparib than with placebo. (Funded by AstraZeneca and Merck; 
SOLO1 ClinicalTrials.gov number, NCT01844986.)
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Standard therapy for patients with newly diagnosed advanced ovarian cancer consists of cytoreductive surgery and plat-
inum-based chemotherapy.1,2 Although the ma-
jority of such patients have no evidence of disease 
after treatment, approximately 70% have a relapse 
within the subsequent 3 years.2 Recurrent ovarian 
cancer is typically incurable, with most patients 
receiving multiple additional lines of treatment 
before ultimately dying from the disease.
In primary analyses of phase 3 trials, the ad-
dition of intravenous bevacizumab to carboplatin 
plus paclitaxel (followed by bevacizumab alone) 
led to prolonged progression-free survival among 
patients with newly diagnosed advanced ovarian 
cancer, with hazard ratios for disease progression 
or death of 0.72 (Burger et al.3) and 0.81 (Perren 
et al.4). However, there was no improvement in 
overall survival.5
Poly(adenosine diphosphate–ribose) polymerase 
(PARP) inhibitors, such as olaparib, trap PARP on 
DNA at sites of single-strand breaks, thereby pre-
venting the repair of the single-strand breaks and 
generating double-strand breaks that cannot be 
repaired accurately in tumors that have defects in 
homologous recombination repair, such as tumors 
with a mutation in BRCA1 or BRCA2. The use of 
PARP inhibitors leads to an accumulation of DNA 
damage and tumor-cell death.6
Olaparib has been approved in the United 
States and Europe as maintenance treatment for 
women with platinum-sensitive relapsed ovarian 
cancer who have a response to their most recent 
platinum-based regimen, regardless of BRCA mu-
tation status.7,8 It has also been approved in the 
United States for the treatment of women with 
advanced ovarian cancer and a deleterious or sus-
pected deleterious germline BRCA mutation who 
have been treated with three or more lines of 
chemotherapy, regardless of sensitivity to plati-
num-based therapy.7 National Comprehensive Can-
cer Network guidelines state that maintenance 
therapy with a PARP inhibitor should be consid-
ered in patients with relapsed ovarian cancer with 
sensitivity to platinum-based therapy, regardless 
of BRCA mutation status.1 We conducted the phase 
3 SOLO1 trial to evaluate the efficacy of mainte-
nance therapy with a PARP inhibitor (olaparib) in 
patients with newly diagnosed advanced ovarian 
cancer with a germline or somatic mutation in 
BRCA1, BRCA2, or both (BRCA1/2) who had a com-
plete or partial clinical response after platinum-
based chemotherapy.
Me thods
Patients
Patients were eligible if they were 18 years of age 
or older and had newly diagnosed, histologically 
confirmed advanced (International Federation of 
Gynecology and Obstetrics stage III or IV) high-
grade serous or endometrioid ovarian cancer, pri-
mary peritoneal cancer, or fallopian-tube cancer 
(or a combination thereof). Those with stage III 
disease had undergone an attempt at cytoreductive 
surgery before the start chemotherapy (up front) 
or after the start but before the end of chemo-
therapy (interval). Those with stage IV disease had 
undergone either biopsy or up-front or interval 
cytoreductive surgery. Eligible patients had a del-
eterious or suspected deleterious germline or so-
matic BRCA1/2 mutation, as determined by local 
or central testing, with the use of the BRACAnalysis 
test (Myriad) or, in China, with the use of a 
BRCA1/2 genetic testing assay (BGI). Germline 
BRCA1/2 mutation status that was determined lo-
cally was confirmed centrally at Myriad or BGI, 
and tumor BRCA1/2 mutation status was assessed 
retrospectively at Foundation Medicine. Eligible 
patients also had received platinum-based chemo-
therapy without bevacizumab and were having a 
complete clinical response (no evidence of disease 
on imaging after chemotherapy and a normal 
CA-125 level) or a partial clinical response (a ≥30% 
decrease in tumor volume from the start to the 
end of chemotherapy or no evidence of disease on 
imaging after chemotherapy but a CA-125 level 
above the upper limit of the normal range). Fur-
ther details and a complete list of eligibility cri-
teria are provided in the Methods section in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org. All the patients 
provided written informed consent.
Trial Design and Interventions
This randomized, double-blind, placebo-controlled, 
phase 3 trial was conducted in 15 countries. Ran-
domization was performed centrally with a block 
design, with stratification according to clinical re-
sponse after platinum-based chemotherapy (com-
plete or partial). Patients were assigned to a trial 
group through an interactive Web-based or voice-
response system.
After completion of platinum-based chemo-
therapy, patients were randomly assigned, in a 
2:1 ratio, to receive olaparib tablets (300 mg twice 
daily) or placebo. The trial intervention was con-
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tinued until investigator-assessed objective disease 
progression on imaging (according to modified 
Response Evaluation Criteria in Solid Tumors 
[RECIST], version 1.1), provided that the patient 
was having a benefit and did not meet any dis-
continuation criteria. Patients who had no evi-
dence of disease at 2 years stopped receiving the 
trial intervention, but patients who had a partial 
response at 2 years were permitted to continue 
receiving the trial intervention in a blinded man-
ner. Crossover between trial groups was not speci-
fied in the protocol. After discontinuation of the 
trial intervention, patients could receive treatments 
at the investigators’ discretion.
End Points and Assessments
The primary end point was progression-free sur-
vival as assessed by investigators. Progression-free 
survival was defined as the time from random-
ization to objective disease progression on imag-
ing (according to modified RECIST, version 1.1) 
or death from any cause. Computed tomography 
or magnetic resonance imaging was performed 
at baseline and every 12 weeks for up to 3 years 
and then every 24 weeks, until objective disease 
progression. A sensitivity analysis of progression-
free survival as assessed by blinded independent 
central review was performed. Other sensitivity 
analyses of progression-free survival were also 
performed (see the Methods section in the Sup-
plementary Appendix).
Secondary end points were second progres-
sion–free survival (the time from randomization 
to second disease progression or death), overall 
survival, the time from randomization to the first 
subsequent therapy or death, the time from ran-
domization to the second subsequent therapy or 
death, and health-related quality of life, which 
was assessed with the use of the Trial Outcome 
Index score on the Functional Assessment of Can-
cer Therapy–Ovarian Cancer (FACT-O) question-
naire (see the Methods section in the Supplemen-
tary Appendix). Trial Outcome Index scores range 
from 0 to 100, with higher scores indicating better 
health-related quality of life and a difference of 
10 points indicating a clinically meaningful differ-
ence. FACT-O questionnaires were completed at 
baseline, on day 29, and every 12 weeks for 3 years 
and then every 24 weeks, until the time of data 
cutoff for the primary efficacy analysis. The analy-
sis of health-related quality of life evaluated the 
change from baseline in the Trial Outcome Index 
score for the first 2 years. Adverse events were 
graded with the use of National Cancer Institute 
Common Terminology Criteria for Adverse Events, 
version 4.0.
Trial Oversight
This trial was performed in accordance with the 
principles of the Declaration of Helsinki, Good 
Clinical Practice guidelines, and the AstraZeneca 
policy of bioethics,8 under the auspices of an in-
dependent data and safety monitoring committee. 
The trial was designed by the first and last au-
thors in collaboration with AstraZeneca and the 
Gynecologic Oncology Group. AstraZeneca was 
responsible for overseeing the collection, analy-
sis, and interpretation of the data. All the au-
thors had full access to the data. The manuscript 
was written by the authors, with medical writing 
assistance funded by AstraZeneca and Merck. 
Olaparib is being codeveloped by AstraZeneca 
and Merck, and Merck provided input regarding 
the interpretation of the data. The authors attest 
to the accuracy and completeness of the data and 
the fidelity of the trial to the protocol (available 
at NEJM.org).
Statistical Analysis
We determined that 206 primary end-point events 
(disease progression or death) would provide the 
trial with 90% power, at a two-sided significance 
level of 0.05, to show a significant difference in 
progression-free survival between the olaparib 
group and the placebo group, with a correspond-
ing hazard ratio for disease progression or death 
of 0.62 (assuming a median progression-free sur-
vival of 13 months in the placebo group). Because 
the rate of primary end-point events was lower 
than projected, the protocol was amended such 
that the primary analysis of progression-free sur-
vival was to be performed when approximately 
196 events had occurred (data maturity, approxi-
mately 50%) or when the last patient to undergo 
randomization had done so at least 3 years earlier, 
whichever came first.
Data on efficacy and health-related quality of 
life were summarized and analyzed in the inten-
tion-to-treat population (all patients who under-
went randomization, regardless of the intervention 
that they actually received). Data on safety were 
summarized in the safety population (all patients 
who received ≥1 dose of the trial intervention).
A multiple-testing procedure was used to con-
trol the type I error rate, with a test for progres-
sion-free survival to be performed first, a test for 
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second progression–free survival to be performed 
if the null hypothesis for progression-free sur-
vival were rejected, and a test for overall survival 
to be performed if the results for progression-free 
survival and second progression–free survival were 
significant. The analyses of time to the first sub-
sequent therapy and time to the second subsequent 
therapy were not adjusted for multiple compari-
sons. To describe the potential benefit of olaparib, 
tests for time to the first subsequent therapy, time 
to the second subsequent therapy, and change 
from baseline in the Trial Outcome Index score 
were performed at a two-sided significance level 
of 0.05.
The analysis of progression-free survival was 
performed with a stratified log-rank test, with 
calculation of a hazard ratio, an accompanying 
95% confidence interval, and a P value (see the 
Methods section in the Supplementary Appendix). 
Analyses of second progression–free survival, over-
all survival, time to the first subsequent therapy, 
and time to the second subsequent therapy were 
performed with a method similar to that used 
for the analysis of progression-free survival. The 
analysis of change from baseline in the Trial Out-
come Index score was performed with a mixed-
effects model for repeated measures. The statisti-
cal analysis plan is available with the protocol at 
NEJM.org.
R esult s
Patients
From September 3, 2013, to March 6, 2015, a total 
of 391 patients underwent randomization. All 
260 patients who were assigned to the olaparib 
group and 130 of the 131 patients who were as-
signed to the placebo group received the trial 
intervention; 1 patient in the placebo group de-
cided to withdraw before receiving the interven-
tion (Fig. 1).
The baseline characteristics were well balanced 
between the trial groups (Table 1). At baseline, the 
majority of patients had no evidence of disease, 
a good performance status, and a CA-125 level 
within the normal range.
With regard to BRCA mutation status, 210 pa-
tients underwent randomization on the basis of 
results of local testing and 181 on the basis of 
results of central testing (at Myriad or BGI). Cen-
tral germline testing confirmed that 388 of the 
391 patients had a BRCA1/2 mutation, 1 had a BRCA 
variant of uncertain significance, and 2 had wild-
type BRCA. Testing at Foundation Medicine showed 
that the 2 patients with wild-type BRCA on central 
germline testing had somatic BRCA mutations 
(see the Results section in the Supplementary Ap-
pendix). Overall, of the 210 locally determined 
BRCA mutations, 207 (99%) were confirmed by 
central germline testing.
The median duration of follow-up was 40.7 
months (interquartile range, 34.9 to 42.9) in the 
olaparib group and 41.2 months (interquartile 
range, 32.2 to 41.6) in the placebo group. A total 
of 123 patients (47%) in the olaparib group and 
35 (27%) in the placebo group completed the 
trial intervention at 2 years, in accordance with 
the protocol, and 26 (10%) and 3 (2%), respectively, 
continued to receive the trial intervention beyond 
2 years. Of the patients who received the trial 
intervention beyond 2 years, 13 were still receiv-
ing olaparib and 1 was still receiving placebo at 
the time of data cutoff for the primary analysis 
(May 17, 2018).
Efficacy
The analysis of the primary end point was per-
formed after 198 of the 391 patients had had 
investigator-assessed disease progression or had 
died (data maturity, 51%). In the primary analysis, 
the Kaplan–Meier estimate of the rate of freedom 
from disease progression and from death at 3 years 
was 60% in the olaparib group, as compared with 
27% in the placebo group (hazard ratio for dis-
ease progression or death, 0.30; 95% confidence 
interval [CI], 0.23 to 0.41; P<0.001) (Fig. 2A). The 
median progression-free survival from the end of 
chemotherapy was 13.8 months in the placebo 
group.
In the analysis of progression-free survival as 
assessed by blinded independent central review 
(data maturity, 38%), the Kaplan–Meier estimate 
of the rate of freedom from disease progression 
and from death at 3 years was 69% in the olaparib 
group, as compared with 35% in the placebo group 
(hazard ratio for disease progression or death, 
0.28; 95% CI, 0.20 to 0.39; P<0.001) (Fig. 2B); 
these results are consistent with the benefit of 
olaparib with regard to progression-free survival 
as assessed by investigators. In a sensitivity analy-
sis of investigator-assessed progression-free sur-
vival that was performed to evaluate for possible 
attrition bias, the median progression-free sur-
vival was approximately 36 months longer in the 
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olaparib group than in the placebo group (see the 
Results section and Table S3 of the Supplementary 
Appendix).
The Kaplan–Meier estimate of the rate of free-
dom from investigator-assessed disease progres-
sion and from death was 88% in the olaparib 
group and 51% in the placebo group at 1 year; 
74% and 35%, respectively, at 2 years; 60% and 
27% at 3 years; and 53% and 11% at 4 years (Fig. 
S1 of the Supplementary Appendix). Subgroup 
analyses of progression-free survival are shown 
in Figure 3.
In the analysis of second progression–free 
survival (data maturity, 31%), the Kaplan–Meier 
estimate of the rate of freedom from second dis-
ease progression and from death at 3 years was 
75% in the olaparib group, as compared with 60% 
in the placebo group (hazard ratio for second 
disease progression or death, 0.50; 95% CI, 0.35 to 
0.72; P<0.001). The median second progression–
free survival was 41.9 months in the placebo 
group (Fig. S2 of the Supplementary Appendix).
In an interim analysis of overall survival (data 
maturity, 21%), the Kaplan–Meier estimate of the 
rate of freedom from death at 3 years was 84% 
in the olaparib group and 80% in the placebo 
group (hazard ratio for death, 0.95; 95% CI, 0.60 
to 1.53). The median time to the first subsequent 
therapy or death was 51.8 months in the olapa-
rib group and 15.1 months in the placebo group 
(hazard ratio, 0.30; 95% CI, 0.22 to 0.40). The 
Kaplan–Meier estimate of the rate of freedom 
from the use of a second subsequent therapy and 
from death at 3 years was 74% in the olaparib 
group and 56% in the placebo group (hazard ratio 
for the use of a second subsequent therapy or 
Figure 1. Enrollment, Randomization, and Intervention.
1084 Patients were enrolled
391 Underwent randomization and
were included in efficacy analyses
693 Were excluded
674 Did not meet eligibility criteria
14 Declined to participate
3 Were lost to follow-up
2 Died
260 Were assigned to receive olaparib
260 Received olaparib and were
included in safety analyses
131 Were assigned to receive placebo
1 Did not receive placebo owing to
early withdrawal
130 Received placebo and were
included in safety analyses
35 Completed intervention at 2 yr,
per protocol
94 Discontinued placebo
78 Had disease progression
9 Discontinued for other
reasons
3 Had adverse event
2 Made the decision to
discontinue
1 Met discontinuation criteria
1 Was lost to follow-up
123 Completed intervention at 2 yr,
per protocol
124 Discontinued olaparib
51 Had disease progression
30 Had adverse event
22 Made the decision to
discontinue
11 Discontinued for other
reasons
6 Met discontinuation criteria
3 Had severe violation of
protocol
1 Discontinued for an
unknown reason
13 Patients were still receiving
olaparib at data cutoff
1 Patient was still receiving
placebo at data cutoff
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Characteristic
Olaparib Group  
(N = 260)
Placebo Group  
(N = 131)
no. of patients (%)
Clinical response after platinum-based chemotherapy†
Complete response 213 (82) 107 (82)
Partial response 47 (18) 24 (18)
No. of cycles of platinum-based chemotherapy
4 2 (1) 0
5 2 (1) 1 (1)
6 198 (76) 106 (81)
7 17 (7) 10 (8)
8 18 (7) 7 (5)
9 23 (9) 7 (5)
ECOG performance status
Normal activity 200 (77) 105 (80)
Restricted activity 60 (23) 25 (19)
Missing data 0 1 (1)
Primary tumor location
Ovary 220 (85) 113 (86)
Fallopian tube 22 (8) 11 (8)
Peritoneum 15 (6) 7 (5)
Other‡ 3 (1) 0
International FIGO stage§
Stage III 220 (85) 105 (80)
Stage IV 40 (15) 26 (20)
CA-125 level
≤ULN 247 (95) 123 (94)
>ULN 13 (5) 7 (5)
Missing data 0 1 (1)
Histologic type
Serous 246 (95) 130 (99)
Endometrioid 9 (3) 0
Mixed serous and endometrioid 5 (2) 1 (1)
BRCA mutation¶
BRCA1 191 (73) 91 (69)
BRCA2 66 (25) 40 (31)
BRCA1 and BRCA2 3 (1) 0
*  Percentages may not total 100 because of rounding. ECOG denotes Eastern Cooperative Oncology Group.
†  Complete response was defined as no evidence of disease on imaging (according to modified Response Evaluation 
Criteria in Solid Tumors, version 1.1) after chemotherapy and a normal CA-125 level. Partial response was defined as a 
decrease of at least 30% in tumor volume from the start to the end of chemotherapy or no evidence of disease on im-
aging after chemotherapy but a CA-125 level above the upper limit of the normal range (ULN).
‡  Other tumor locations included a combination of the ovary, fallopian tube, peritoneum, and omentum (in one patient),  
a combination of the ovary and peritoneum (one patient), and a combination of the ovary and fallopian tube (one patient).
§  International Federation of Gynecology and Obstetrics (FIGO) stage III indicates involvement of one or both ovaries 
with cytologically or histologically confirmed spread to the peritoneum outside the pelvis or metastasis to the retroperi-
toneal lymph nodes (or both), and stage IV indicates distant metastasis excluding peritoneal metastasis.
¶  BRCA mutation status was determined centrally (at Myriad or BGI) or locally. For the five patients from China, germ-
line BRCA mutation status was determined in China with the use of the BGI test.
Table 1. Characteristics of the Patients at Baseline.*
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death, 0.45; 95% CI, 0.32 to 0.63), with a median 
time to the second subsequent therapy or death of 
40.7 months in the placebo group.
Safety
The median duration of the trial intervention in 
the olaparib group was 24.6 months (range, 0.0 to 
52.0), a finding consistent with the 2-year treat-
ment cap. The median duration in the placebo 
group was 13.9 months (range, 0.2 to 45.6), a 
finding consistent with the median progression-
free survival in that group (see the Results section 
and Table S4 of the Supplementary Appendix).
The most common adverse events that occurred 
during the trial intervention or up to 30 days after 
discontinuation of the intervention are shown in 
Table 2; most were grade 1 or 2 events. Serious 
adverse events occurred in 21% of the patients in 
the olaparib group and 12% of the patients in the 
placebo group (Table S5 of the Supplementary 
Appendix). Anemia was the most common serious 
adverse event (in 7% of the patients in the olaparib 
group and in no patients in the placebo group). No 
adverse events that occurred during the trial in-
tervention or up to 30 days after discontinuation 
of the intervention resulted in death.
Adverse events were usually managed by dose 
interruption or dose reduction, rather than dis-
continuation (Table 2). The most common adverse 
events that led to discontinuation were nausea and 
anemia (Table S6 of the Supplementary Appendix).
Acute myeloid leukemia occurred in 3 of 260 
patients (1%) in the olaparib group and in none 
of 130 patients in the placebo group, new primary 
cancers occurred in 5 (2%) and 3 (2%), respec-
tively, and pneumonitis or interstitial lung disease 
occurred in 5 (2%) and none (see the Results sec-
tion in the Supplementary Appendix). All three 
cases of acute myeloid leukemia occurred more 
than 30 days after the end of treatment with 
olaparib.
Health-Related Quality of Life
The mean Trial Outcome Index score at baseline 
was 73.6 in the olaparib group and 75.0 in the 
placebo group. The score remained stable in the 
olaparib group (237 patients), with an adjusted 
mean change from baseline to 2 years of 0.30 
points (95% CI, −0.72 to 1.32), as compared with 
a change of 3.30 points (95% CI, 1.84 to 4.76) in 
the placebo group (125 patients) (Fig. S3 of the 
Supplementary Appendix). The estimated between-
group difference in change was −3.00 points (95% 
CI, −4.78 to −1.22); the difference was not con-
sidered to be clinically meaningful.
Discussion
In the phase 3 SOLO1 trial, the use of maintenance 
therapy with olaparib provided a substantial ben-
efit with regard to progression-free survival among 
women with newly diagnosed advanced ovarian 
cancer and a BRCA1/2 mutation, with a 70% lower 
risk of disease progression or death with olaparib 
than with placebo. Results of a sensitivity analysis 
and the time to first subsequent therapy or death 
support an estimated difference in median pro-
gression-free survival between the olaparib group 
and the placebo group of approximately 3 years. 
The median progression-free survival of 13.8 
months in the placebo group, which was mea-
sured from the end of chemotherapy rather than 
from the start of chemotherapy, is consistent 
with results reported in studies of carboplatin 
plus paclitaxel in patients with newly diagnosed 
advanced ovarian cancer and a BRCA1/2 muta-
tion.9,10 The results of sensitivity analyses and 
subgroup analyses of progression-free survival 
were consistent with the results of the primary 
analysis. The absolute longer progression-free sur-
vival with olaparib than with placebo that was seen 
in a sensitivity analysis in this trial was substan-
tially greater than the increases in progression-
free survival that were seen with PARP inhibitors 
in relapsed disease,11-13 and some patients (e.g., 
those who have platinum resistance) are not eli-
gible to receive olaparib as a second-line therapy. 
Some patients in this trial were able to stop re-
ceiving the trial intervention at 2 years and to 
live progression-free for months without treat-
ment. Patients with newly diagnosed advanced 
ovarian cancer are the only patients with ovarian 
cancer in whom treatment has curative potential. 
Ongoing follow-up of patients in this trial would 
be necessary to evaluate whether a subgroup has 
a durable long-term benefit with olaparib (which 
has been seen in relapsed disease with sensitiv-
ity to platinum-based therapy14) or even a cure.
A significant increase in time to second dis-
ease progression was also noted with olaparib, a 
finding that suggests that olaparib did not di-
minish patients’ ability to benefit from subse-
quent therapy. This finding was observed despite 
the use of PARP inhibitors in 33 of 94 patients 
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Figure 2. Kaplan–Meier Estimates of Progression-free Survival.
Panel A shows Kaplan–Meier estimates of the rate of freedom from disease progression, as assessed by investiga-
tors, and from death in the olaparib group and the placebo group. There was no evidence of a change in the shape 
of the Kaplan–Meier curve for olaparib after 24 months, when patients with no evidence of disease stopped the in-
tervention, in accordance with the protocol; this finding indicates a sustained benefit of olaparib beyond the com-
pletion of treatment. In a sensitivity analysis of investigator-assessed progression-free survival that was performed 
to evaluate for possible attrition bias, the median progression-free survival was approximately 36 months longer in 
the olaparib group than in the placebo group (see the Supplementary Appendix). Panel B shows Kaplan–Meier esti-
mates of the rate of freedom from disease progression, as assessed by blinded independent central review, and 
from death. The dashed line indicates the median.
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(35%) in the placebo group who received subse-
quent therapy, which may potentially explain the 
median second progression–free survival of 42 
months in the placebo group. Data on overall sur-
vival are currently immature but show no evidence 
that olaparib had a detrimental effect on survival.
Most patients in this trial had a germline 
BRCA1/2 mutation. However, the results of other 
studies11,12 suggest that the findings could be 
applicable to patients with a somatic BRCA1/2
mutation.
The safety profile of olaparib in the SOLO1 trial 
was consistent with that seen in patients with 
relapsed disease (i.e., in patients in the SOLO2 
trial13), despite the longer duration of treatment. 
Rates of adverse events that led to dose reduction 
or discontinuation were relatively low. The safety 
profile of olaparib appeared to be generally accept-
able in patients receiving maintenance treatment 
for newly diagnosed advanced ovarian cancer.
The incidence of acute myeloid leukemia that 
was reported in the SOLO1 trial (1%) is consistent 
with the incidence of the myelodysplastic syn-
drome or acute myeloid leukemia that was report-
ed in the SOLO2 trial (2%)13 and other trials of 
PARP inhibitors.11,12,15 Comparative data regarding 
the incidence of the myelodysplastic syndrome 
or acute myeloid leukemia after the use of plati-
Figure 3. Subgroup Analysis of Progression-free Survival.
For the hazard ratios, the size of the circle is proportional to the number of events. The gray band represents the 95% confidence inter-
val for all patients, and the dashed line indicates the point of no effect. International Federation of Gynecology and Obstetrics (FIGO) 
stage III indicates involvement of one or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside 
the pelvis or metastasis to the retroperitoneal lymph nodes (or both), and stage IV indicates distant metastasis excluding peritoneal 
metastasis. NC denotes not calculated, ECOG Eastern Cooperative Oncology Group, and ULN upper limit of the normal range.
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num-based chemotherapy alone in patients with 
newly diagnosed ovarian cancer are limited.
In this trial, neither trial group had a clinically 
significant change in health-related quality of life. 
Although there was a between-group difference in 
the change in the Trial Outcome Index score, the 
difference was less than 10 points and thus was 
not considered to be clinically meaningful.16
In conclusion, the SOLO1 trial showed that 
the use of maintenance therapy with olaparib, as 
compared with placebo, after platinum-based che-
motherapy provided a substantial benefit with 
regard to progression-free survival among women 
with newly diagnosed advanced ovarian cancer and 
a BRCA1/2 mutation.
Supported by AstraZeneca and Merck.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Adverse Event Olaparib (N = 260) Placebo (N = 130)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
number of patients (percent)
Any 256 (98) 102 (39) 120 (92) 24 (18)
Nausea 201 (77) 2 (1) 49 (38) 0
Fatigue or asthenia 165 (63) 10 (4) 54 (42) 2 (2)
Vomiting 104 (40) 1 (<1) 19 (15) 1 (1)
Anemia† 101 (39) 56 (22) 13 (10) 2 (2)
Diarrhea 89 (34) 8 (3) 32 (25) 0
Constipation 72 (28) 0 25 (19) 0
Dysgeusia 68 (26) 0 5 (4) 0
Arthralgia 66 (25) 0 35 (27) 0
Abdominal pain 64 (25) 4 (2) 25 (19) 1 (1)
Neutropenia‡ 60 (23) 22 (9) 15 (12) 6 (5)
Headache 59 (23) 1 (<1) 31 (24) 3 (2)
Dizziness 51 (20) 0 20 (15) 1 (<1)
Decreased appetite 51 (20) 0 13 (10) 0
Upper abdominal pain 46 (18) 0 17 (13) 0
Dyspepsia 43 (17) 0 16 (12) 0
Cough 42 (16) 0 28 (22) 0
Back pain 40 (15) 0 16 (12) 0
Dyspnea 39 (15) 0 7 (5) 0
Thrombocytopenia§ 29 (11) 2 (1) 5 (4) 2 (2)
Led to discontinuation of intervention 30 (12) NA 3 (2) NA
Led to dose reduction 74 (28) NA 4 (3) NA
Led to dose interruption 135 (52) NA 22 (17) NA
*  Shown are data on adverse events that occurred in at least 15% of the patients in either trial group (except where  
noted) during the trial intervention or up to 30 days after discontinuation of the intervention. The adverse events were 
graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.  
NA denotes not available.
†  The data include patients with anemia, a decreased hemoglobin level, a decreased hematocrit, a decreased red-cell count, 
erythropenia, macrocytic anemia, normochromic anemia, normochromic normocytic anemia, or normocytic anemia.
‡  The data include patients with neutropenia, febrile neutropenia, neutropenic sepsis, neutropenic infection, a decreased 
neutrophil count, idiopathic neutropenia, granulocytopenia, a decreased granulocyte count, or agranulocytosis.
§  Thrombocytopenia occurred in less than 15% of the patients in each trial group, but the data are provided to complete 
the profile of hematologic toxic effects. The data include patients with thrombocytopenia, decreased platelet produc-
tion, decreased platelet count, or decreased plateletcrit.
Table 2. Summary of Adverse Events.*
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